Incident Antipsychotic Use

    Basic Details
    Date Posted
    Friday, May 20, 2016
    Status
    Complete
    Medical Product
    antipsychotic
    aripiprazole
    asenapine
    clozapine
    iloperidone
    lurasidone
    olanzapine
    paliperidone
    quetiapine
    risperidone
    ziprasidone
    Description

    Modular program-based one-time assessment of the incident use of antipsychotics, including aripiprazole, asenapine, clozapine, iloperidone, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone, among patients without a pre-existing condition of schizophrenia spectrum disorder or bipolar I disorder and those with a pre-existing condition of schizophrenia spectrum disorder or bipolar I disorder. The query was run against the Mini-Sentinel Distributed Database (MSDD) for the time period of August 1, 2009 to September 30, 2011.  Modular programs are adaptable standardized programs. Results were generated using Modular Program 3; click here for more information.  Queries were distributed in October 2012. This report includes data from 16 Data Partners.
     
    If you are using a web page screen reader and are unable to access this document, please contact the Mini-Sentinel Operations Center for assistance by clicking on the Submit Comments link above or sending an email requesting assistance to info@mini-sentinel.org.
     
    The information contained on this website is provided as part of FDA's commitment to place knowledge acquired from the Mini-Sentinel pilot in the public domain as soon as possible. Please read the disclaimer.

    Additional Details
    FDA Center
    CDER
    Time Period
    August 1, 2009 - September 30, 2011
    Study Type
    Modular Program
    Assessment Type
    Exploratory Analyses
    Population / Cohort
    All individuals
    Data Sources
    Mini-Sentinel Distributed Database (MSDD)